Pursuant to the Gemma Collaboration Agreement, (i) Gemma will conduct certain preclinical and Investigational New Drug, or IND, enabling work for the Company’s active research program in Huntington’s…
the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage…
Reciprocal relationship from PENN graph: Reciprocal relationship from PASG graph: the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tier…
Passage Bio, Inc. Customers
No clients on recordNo downstream customers found in our database for Passage Bio, Inc..
Passage Bio, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PASG-DEBT
Debt stack $5.8M
90%
Market cache reports total debt of $5.8M.
Passage Bio, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Passage Bio, Inc..
Passage Bio, Inc. Ownership
Holder
Name
Confidence
Evidence
PASG-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 1 tracked holders.